JP2014074724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014074724A5 JP2014074724A5 JP2014006601A JP2014006601A JP2014074724A5 JP 2014074724 A5 JP2014074724 A5 JP 2014074724A5 JP 2014006601 A JP2014006601 A JP 2014006601A JP 2014006601 A JP2014006601 A JP 2014006601A JP 2014074724 A5 JP2014074724 A5 JP 2014074724A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- amount
- biological sample
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 34
- 238000000034 method Methods 0.000 claims 25
- 201000011510 cancer Diseases 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 239000012472 biological sample Substances 0.000 claims 9
- 239000000556 agonist Substances 0.000 claims 7
- 238000003556 assay Methods 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000833 heterodimer Substances 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000000710 homodimer Substances 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- JXLVPHOTGHZUCE-ZSIUJALASA-N methyl n-[4-[5-chloro-2-[(1s)-1-[[(e)-3-[5-chloro-2-(tetrazol-1-yl)phenyl]prop-2-enoyl]amino]-3-morpholin-4-yl-3-oxopropyl]-1h-imidazol-4-yl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=C(Cl)NC([C@H](CC(=O)N2CCOCC2)NC(=O)\C=C\C=2C(=CC=C(Cl)C=2)N2N=NN=C2)=N1 JXLVPHOTGHZUCE-ZSIUJALASA-N 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 230000004850 protein–protein interaction Effects 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14502909P | 2009-01-15 | 2009-01-15 | |
| US61/145,029 | 2009-01-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546408A Division JP2012515353A (ja) | 2009-01-15 | 2010-01-15 | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014074724A JP2014074724A (ja) | 2014-04-24 |
| JP2014074724A5 true JP2014074724A5 (enExample) | 2014-08-28 |
| JP5615986B2 JP5615986B2 (ja) | 2014-10-29 |
Family
ID=42340111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546408A Withdrawn JP2012515353A (ja) | 2009-01-15 | 2010-01-15 | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
| JP2014006601A Active JP5615986B2 (ja) | 2009-01-15 | 2014-01-17 | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546408A Withdrawn JP2012515353A (ja) | 2009-01-15 | 2010-01-15 | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20100233732A1 (enExample) |
| EP (1) | EP2387717B1 (enExample) |
| JP (2) | JP2012515353A (enExample) |
| KR (1) | KR20110120890A (enExample) |
| CN (1) | CN102439452B (enExample) |
| AU (1) | AU2010204576A1 (enExample) |
| BR (1) | BRPI1007048A2 (enExample) |
| CA (1) | CA2749817A1 (enExample) |
| ES (1) | ES2526519T3 (enExample) |
| IL (1) | IL214067A0 (enExample) |
| SG (1) | SG172984A1 (enExample) |
| WO (1) | WO2010083463A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| US20040091850A1 (en) * | 2002-11-08 | 2004-05-13 | Travis Boone | Single cell analysis of membrane molecules |
| US7402398B2 (en) | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| WO2009070772A1 (en) | 2007-11-27 | 2009-06-04 | Monogram Biosciences, Inc. | Enhanced method for detecting and/or quantifying an analyte in a sample |
| US10416162B2 (en) | 2007-12-20 | 2019-09-17 | Monogram Biosciences, Inc. | Her2 diagnostic methods |
| ES2637411T3 (es) | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| US11401344B2 (en) | 2008-12-01 | 2022-08-02 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
| ES2535723T3 (es) | 2009-01-15 | 2015-05-14 | Laboratory Corporation Of America Holdings | Métodos de determinación de la respuesta del paciente mediante la medición de Her-3 |
| WO2012015765A2 (en) | 2010-07-27 | 2012-02-02 | Genomic Health, Inc. | Method for using gene expression to determine prognosis of prostate cancer |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| ES2701929T3 (es) | 2011-05-19 | 2019-02-26 | Laboratory Corp America Holdings | Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer |
| FR2993668B1 (fr) * | 2012-07-17 | 2015-07-03 | Cisbio Bioassays | Methode theranostique basee sur la detection de dimeres her2-her2 |
| WO2014165855A1 (en) | 2013-04-05 | 2014-10-09 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
| WO2016083364A1 (en) * | 2014-11-25 | 2016-06-02 | Ventana Medical Systems, Inc. | Proximity assays using chemical ligation and hapten transfer |
| WO2017014694A1 (en) * | 2015-07-23 | 2017-01-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
| JP2019515252A (ja) | 2016-03-15 | 2019-06-06 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | 細胞間のタンパク質相互作用を評価する方法 |
| PL3519437T3 (pl) | 2016-09-30 | 2022-01-17 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste przeciwko p95HER2 |
| JP6922444B2 (ja) * | 2016-11-11 | 2021-08-18 | コニカミノルタ株式会社 | 蛍光ナノ粒子を用いた、病理学的完全奏効（ｐＣＲ）の予測を支援するための検査支援方法 |
| WO2019241599A1 (en) * | 2018-06-14 | 2019-12-19 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies |
| KR102317202B1 (ko) * | 2018-10-19 | 2021-10-25 | 주식회사 프로티나 | 유방암 재발 예측 방법 |
| KR20230134232A (ko) | 2022-03-14 | 2023-09-21 | 부산대학교 산학협력단 | 백금계 항암제에 대한 난소암 환자의 약물 반응성 예측용 다중 바이오마커 조성물 및 이를 이용한 진단방법 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995026403A1 (en) * | 1994-03-29 | 1995-10-05 | Celltech Therapeutics Limited | Antibodies against e-selectin |
| SE9601676D0 (sv) * | 1996-04-30 | 1996-04-30 | Ulf Landegren | Improved probing of specific mucleic acids |
| US6335479B1 (en) * | 1998-10-13 | 2002-01-01 | Dai Nippon Printing Co., Ltd. | Protective sheet for solar battery module, method of fabricating the same and solar battery module |
| US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
| US6627400B1 (en) * | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
| US6682887B1 (en) * | 1999-04-30 | 2004-01-27 | Aclara Biosciences, Inc. | Detection using degradation of a tagged sequence |
| US20040248150A1 (en) * | 1999-04-02 | 2004-12-09 | Sharat Singh | Methods employing oligonucleotide-binding e-tag probes |
| US6322980B1 (en) * | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
| US6514700B1 (en) * | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
| US20030235832A1 (en) * | 2000-06-21 | 2003-12-25 | Ahmed Chenna | Multiplexed analysis by chromatographic separation of molecular tags |
| US6673550B2 (en) * | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
| US7001725B2 (en) * | 1999-04-30 | 2006-02-21 | Aclara Biosciences, Inc. | Kits employing generalized target-binding e-tag probes |
| US7037654B2 (en) * | 1999-04-30 | 2006-05-02 | Aclara Biosciences, Inc. | Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents |
| US20030092012A1 (en) * | 2001-11-09 | 2003-05-15 | Ahmed Chenna | Methods for detecting a plurality of analytes by chromatography |
| US6649351B2 (en) * | 1999-04-30 | 2003-11-18 | Aclara Biosciences, Inc. | Methods for detecting a plurality of analytes by mass spectrometry |
| US6162593A (en) * | 1999-10-26 | 2000-12-19 | Wyatt; Marion F. | Diisopropylbenzene containing solvent and method of developing flexographic printing plates |
| DE19963849A1 (de) * | 1999-12-30 | 2001-07-12 | Giesecke & Devrient Gmbh | Datenträger mit gedrucktem Sicherheitselement |
| US7306904B2 (en) * | 2000-02-18 | 2007-12-11 | Olink Ab | Methods and kits for proximity probing |
| US6743911B2 (en) * | 2000-03-14 | 2004-06-01 | Shell Oil Company | Process for the carbonylation of pentenenitrile |
| GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
| US7160735B2 (en) * | 2000-04-28 | 2007-01-09 | Monogram Biosciences, Inc. | Tagged microparticle compositions and methods |
| US7771929B2 (en) * | 2000-04-28 | 2010-08-10 | Monogram Biosciences, Inc. | Tag library compounds, compositions, kits and methods of use |
| US7537938B2 (en) * | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
| US7255999B2 (en) * | 2001-05-21 | 2007-08-14 | Monogram Biosciences, Inc. | Methods and compositions for analyzing proteins |
| US20040067498A1 (en) * | 2000-04-28 | 2004-04-08 | Ahmed Chenna | Detection of nucleic acid sequences by cleavage and separation of tag-containing structures |
| US20030207300A1 (en) * | 2000-04-28 | 2003-11-06 | Matray Tracy J. | Multiplex analytical platform using molecular tags |
| EP1309717A1 (en) * | 2000-08-08 | 2003-05-14 | Aclara BioSciences, Inc. | Multiplexed enzymatic assays |
| ES2394293T3 (es) * | 2001-02-28 | 2013-01-30 | Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. | Vacuna contra cánceres que están asociados con el oncogén HER-2/neu |
| US7183388B2 (en) * | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
| WO2002094998A2 (en) * | 2001-05-21 | 2002-11-28 | Aclara Biosciences, Inc. | Analyzing phosphorylated proteins |
| US7358052B2 (en) * | 2001-05-26 | 2008-04-15 | Monogram Biosciences, Inc. | Catalytic amplification of multiplexed assay signals |
| US7446185B2 (en) * | 2001-07-18 | 2008-11-04 | The Regents Of The University Of California | Her2/neu target antigen and use of same to stimulate an immune response |
| US20040241688A1 (en) * | 2001-07-19 | 2004-12-02 | Cuneyt Bukusoglu | Human tissue specific drug screening procedure |
| GB2378245A (en) * | 2001-08-03 | 2003-02-05 | Mats Nilsson | Nucleic acid amplification method |
| WO2003033741A1 (en) * | 2001-10-16 | 2003-04-24 | Aclara Biosciences, Inc. | Universal e-tag primer and probe compositions and methods |
| US7045311B2 (en) * | 2001-10-25 | 2006-05-16 | Monogram Biosciences, Inc. | Whole cell assay systems for cell surface proteases |
| US6659577B2 (en) * | 2001-12-06 | 2003-12-09 | Hewlett-Packard Development Company, L.P. | Dual flat springs for tool-less slide installation |
| US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
| KR101048894B1 (ko) * | 2002-02-26 | 2011-07-13 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 항-인간 테나신 단클론 항체 |
| US6949347B2 (en) * | 2002-03-05 | 2005-09-27 | Aclara Biosciences, Inc. | Multiplex analysis using membrane-bound sensitizers |
| EP3115470B1 (en) * | 2002-03-13 | 2018-07-18 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| WO2003085374A2 (en) * | 2002-04-02 | 2003-10-16 | Aclara Biosciences, Inc. | Multiplexed assays using electrophoretically separated molecular tags |
| US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| US20040229293A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | Surface receptor complexes as biomarkers |
| US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
| US20090111127A1 (en) * | 2002-05-21 | 2009-04-30 | Monogram Biosciences Inc. | Surface Receptor Complexes as Biomarkers |
| US7402397B2 (en) * | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| US20040229299A1 (en) * | 2002-05-21 | 2004-11-18 | Badal M. Youssouf | Intracellular complexes as biomarkers |
| US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| US20040175765A1 (en) * | 2002-07-05 | 2004-09-09 | Sharat Singh | Cell-screening assay and composition |
| PT2263691E (pt) * | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
| CN1672054A (zh) * | 2002-07-25 | 2005-09-21 | 阿克拉若生物科学公司 | 检测受体寡聚化 |
| JP2006508907A (ja) * | 2002-07-26 | 2006-03-16 | アクララ バイオサイエンシーズ， インコーポレイテッド | 親油性電気泳動プローブ |
| US20040091850A1 (en) * | 2002-11-08 | 2004-05-13 | Travis Boone | Single cell analysis of membrane molecules |
| BRPI0408950A (pt) * | 2003-04-01 | 2006-03-28 | Monogram Biosciences Inc | método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica |
| US20100291594A1 (en) * | 2003-07-17 | 2010-11-18 | Laboratory Corporation Of America Holdings | ErbB Surface Receptor Complexes as Biomarkers |
| US7402398B2 (en) * | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| US20060204966A1 (en) * | 2003-08-01 | 2006-09-14 | Spector Neil L | Treatment of cancers expressing p95 erbb2 |
| EP1673399B1 (en) * | 2003-08-11 | 2017-04-05 | Monogram BioSciences, Inc. | Detecting and profiling molecular complexes |
| EP1664716A4 (en) * | 2003-08-15 | 2008-08-13 | Smithkline Beecham Corp | CANCER BIOMARKERS |
| US20050106571A1 (en) * | 2003-10-02 | 2005-05-19 | The Regents Of The University Of California | Mammalian T1R3 sweet taste receptors |
| WO2005037071A2 (en) * | 2003-10-14 | 2005-04-28 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
| JP4011100B2 (ja) * | 2004-07-09 | 2007-11-21 | 中外製薬株式会社 | 抗グリピカン３抗体 |
| WO2006044748A2 (en) * | 2004-10-15 | 2006-04-27 | Monogram Biosciences, Inc. | RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS |
| WO2006137932A2 (en) * | 2004-11-03 | 2006-12-28 | Leucadia Technologies, Inc. | Homogeneous analyte detection |
| US7939267B2 (en) * | 2004-11-04 | 2011-05-10 | Laboratory Corporation Of America Holdings | Detection of activation of endothelial cells as surrogate marker for angiogenesis |
| US7862995B2 (en) * | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| US20060212956A1 (en) * | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| CN1928563B (zh) * | 2005-09-09 | 2010-04-28 | 上海张江生物技术有限公司 | 乳腺癌的免疫组化诊断试剂盒和测试片 |
| WO2009070772A1 (en) * | 2007-11-27 | 2009-06-04 | Monogram Biosciences, Inc. | Enhanced method for detecting and/or quantifying an analyte in a sample |
| CN101230390A (zh) * | 2007-12-07 | 2008-07-30 | 湖北大学 | 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法 |
| US10416162B2 (en) * | 2007-12-20 | 2019-09-17 | Monogram Biosciences, Inc. | Her2 diagnostic methods |
| ES2637411T3 (es) * | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| ES2535723T3 (es) * | 2009-01-15 | 2015-05-14 | Laboratory Corporation Of America Holdings | Métodos de determinación de la respuesta del paciente mediante la medición de Her-3 |
-
2010
- 2010-01-15 BR BRPI1007048A patent/BRPI1007048A2/pt not_active Application Discontinuation
- 2010-01-15 JP JP2011546408A patent/JP2012515353A/ja not_active Withdrawn
- 2010-01-15 EP EP10732178.8A patent/EP2387717B1/en not_active Revoked
- 2010-01-15 ES ES10732178.8T patent/ES2526519T3/es active Active
- 2010-01-15 US US12/688,766 patent/US20100233732A1/en not_active Abandoned
- 2010-01-15 CA CA2749817A patent/CA2749817A1/en not_active Abandoned
- 2010-01-15 SG SG2011051000A patent/SG172984A1/en unknown
- 2010-01-15 CN CN201080009544.4A patent/CN102439452B/zh not_active Expired - Fee Related
- 2010-01-15 WO PCT/US2010/021272 patent/WO2010083463A1/en not_active Ceased
- 2010-01-15 KR KR1020117018898A patent/KR20110120890A/ko not_active Withdrawn
- 2010-01-15 AU AU2010204576A patent/AU2010204576A1/en not_active Abandoned
-
2011
- 2011-07-13 IL IL214067A patent/IL214067A0/en unknown
-
2014
- 2014-01-17 JP JP2014006601A patent/JP5615986B2/ja active Active
- 2014-07-02 US US14/322,317 patent/US20140370523A1/en not_active Abandoned
-
2016
- 2016-06-15 US US15/183,151 patent/US20170082626A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014074724A5 (enExample) | ||
| Toki et al. | High-plex predictive marker discovery for melanoma immunotherapy–treated patients using digital spatial profiling | |
| Gerdes et al. | Emerging understanding of multiscale tumor heterogeneity | |
| Chua et al. | Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review | |
| JP5615986B2 (ja) | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 | |
| JP2012515353A5 (enExample) | ||
| Adackapara et al. | Immunohistochemistry using the BRAF V600E mutation‐specific monoclonal antibody VE 1 is not a useful surrogate for genotyping in colorectal adenocarcinoma | |
| US10416162B2 (en) | Her2 diagnostic methods | |
| Hutchinson et al. | Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer | |
| Berezowska et al. | Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas | |
| Gruber et al. | A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry | |
| JP2016517960A5 (enExample) | ||
| JP2016536568A5 (enExample) | ||
| US20130216523A1 (en) | Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression | |
| Monteiro et al. | Phosphorylated EGFR at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas | |
| Akagi et al. | Visinin‐like protein‐1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients | |
| Li et al. | HER-2 overexpression and survival in colorectal cancer: a meta-analysis | |
| Devriese et al. | Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials | |
| Ramić et al. | Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer | |
| JP6626037B2 (ja) | 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法 | |
| Kopljar et al. | High expression of DARPP-32 in colorectal cancer is associated with liver metastases and predicts survival for Dukes A and B patients: results of a pilot study | |
| Sato et al. | Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2 | |
| Yu et al. | Evaluation of expression of the Wnt signaling components in canine mammary tumors via RT2 Profiler PCR Array and immunochemistry assays | |
| Miyai et al. | Frequent EGFR expression/EGFR amplification and lack of activating mutation in testicular choriocarcinoma | |
| Lacambra et al. | Anterior gradient 2 is a poor outcome indicator in luminal breast cancer |